Biochem/physiol Actions
Reversible: no
Primary TargetAdenylate cyclase
Product does not compete with ATP.
Target IC50: 250 µM against adenylate cyclase
Cell permeable: yes
General description
Cell-permeable and irreversible inhibitor of adenylate cyclase (IC50 = 250 µM).
Cell-permeable irreversible inhibitor of adenylate cyclase (IC50 = 250 µM).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Correia-de-Sa, P., and Ribeiro, J.A. 1994. Eur. J. Pharmacol. 271, 349.Gorczynska, E., et al. 1994. Endocrinology134, 293.Delpiano, M.A., and Acker, H. 1991. J. Neurochem.57, 291.Lippe, C., and Ardizzone, C. 1991. Comp. Biochem. Physiol.99, 209.Guellaen, G., et al. 1977. Biochim. Biophys. Acta 484, 465.
Packaging
1 mg in Plastic ampoule
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: